Prostatype Genomics AB (publ)
PROGEN
Rank in Stocks
#33659
Prostatype Genomics AB focuses on creating, marketing, and selling... Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Share Price
$0.01025363
Last synced: 2026-11-09
Market Cap
$338.37K
Change (1 day)
2.86%
Change (1 year)
-84.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prostatype Genomics AB (publ) (PROGEN)
Category
Healthcare
Operating Margin for Prostatype Genomics AB (publ) (PROGEN)
Operating Margin as of November 2026 TTM: -3,694.18%
According to Prostatype Genomics AB (publ)'s latest financial reports, its current operating margin (TTM) is -3,694.18%. At the end of 2025 the company had an operating margin of -6,579.12%.
Operating Margin history for Prostatype Genomics AB (publ) from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3,694.18% | -43.85% |
| 2025 | -6,579.12% | -67.95% |
| 2024 | -20,529.15% | 609.29% |
| 2023 | -2,894.32% | -31.09% |
| 2022 | -4,200.44% | -97.30% |
| 2021 | -155,482.65% | 6,298.38% |
| 2020 | -2,430.03% | -77.10% |
| 2019 | -10,609.83% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.00% |
US
|
|
| 20.38% | -100.01% |
US
|
|
| 43.02% | -100.01% |
CN
|
|
| 32.03% | -100.01% |
US
|
|
| 22.23% | -100.01% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Prostatype Genomics AB (publ)'s operating margin
What is Prostatype Genomics AB (publ)'s operating margin?
Prostatype Genomics AB (publ)'s operating margin is -3,694.18%, as of Nov 2026.
What was Prostatype Genomics AB (publ)'s operating margin in 2025?
In 2025, Prostatype Genomics AB (publ)'s operating margin was -6,579.12%, compared with -20,529.15% in 2024.
How has Prostatype Genomics AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Prostatype Genomics AB (publ)'s operating margin was highest in 2020 (-2,430.03%) and lowest in 2021 (-155,482.65%).
How does Prostatype Genomics AB (publ)'s operating margin compare with similar companies?
Prostatype Genomics AB (publ)'s operating margin (-3,694.18%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.